Rapidly progressive invasive pulmonary aspergillosis in a diabetic man

Komase, Yuko; Kunishima, Hiroyuki; Yamaguchi, Hiromichi; Ikehara, Mizuki; Yamamoto, Takahito; Shinagawa, Toshihito

doi:10.1007/s10156-006-0481-8

Cited by 10 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The highest risk populations for invasive aspergillosis comprise chronic granulomatous disease, prolonged neutropenia, HSCT and heart, lung and pancreas organ transplantation [ 99 , 100 ]. Other lower risk patients include those with COPD [ 4 ], high dose corticosteroid treatment [ 101 ], lung cancer [ 102 ], liver cirrhosis [ 103 , 104 ], renal and liver transplantation [ 105 ], diabetes mellitus [ 106 ] and sepsis, especially in the ICU setting [ 107 ]. The global incidence of invasive aspergillosis was previously reported to be 200,000 cases with an associated mortality ranging from 30–80% [ 108 ], recently updated to >300,000 cases [ 20 ].…”

Section: Estimate Precisionmentioning

confidence: 99%

Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision

Bongomin

Gago

Oladele

et al. 2017

JoF

2,028

1,745

View full text Add to dashboard Cite

Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.

show abstract

Section: Estimate Precisionmentioning

confidence: 99%

Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision

Bongomin

Gago

Oladele

et al. 2017

JoF

2,028

1,745

View full text Add to dashboard Cite

show abstract

“…Case reports have also described IPA in immunocompetent but critically ill patients with risk factors such as cirrhosis, chronic obstructive pulmonary disease, chronic alcohol abuse, burn injury, diabetes, malnutrition, and Influenza infection (Bagdasarian, 2012; Carfagna et al, 2011; Clancy and Nguyen, 1998; Guinea et al, 2010; Hovenden et al, 1991; Janes et al, 1998; Karam and Griffin, 1986; Komase et al, 2007; Samarakoon and Soubani, 2008; Sridhar et al, 2012; Stevens and Melikian, 2011). Our report describes two fatal cases of pathologically confirmed invasive aspergillosis in immunocompetent patients with Influenza in an intensive care unit (ICU) setting, and details and summarizes the relevant literature.…”

Section: Introductionmentioning

confidence: 99%

Invasive pulmonary aspergillosis and influenza co-infection in immunocompetent hosts: case reports and review of the literature

Shah

Hsiao

Kirsch

et al. 2018

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

Invasive pulmonary aspergillosis (IPA) is classically considered an illness of severely immunocompromised patients with limited host defenses. However, IPA has been reported in immunocompetent but critically ill patients. This report describes two fatal cases of pathologically confirmed IPA in patients with Influenza in the intensive care unit. One patient had Influenza B infection, whereas the other had Influenza A H1N1. Both patients died despite broad-spectrum antimicrobials, mechanical ventilation, and vasopressor support. Microscopic and histologic postmortem examination confirmed IPA. Review of the English language and foreign literature indicates that galactomannan antigen testing and classic radiologic findings for IPA may not be reliable in immunocompetent patients. Respiratory cultures which grow Aspergillus species in critically ill patients, particularly those with underlying Influenza infection, should not necessarily be disregarded as contaminants or colonizers. Further research is needed to better understand the immunological relationship between Influenza and IPA for improved prevention and treatment of Influenza and Aspergillus co-infections.

show abstract

“…The current patient with Aspergillus duodenitis lacked definitive risk factors for Aspergillus infection but had mild risk factors for invasive aspergillosis of cirrhosis,2,3 diabetes,4 and alcoholism. Literature review did not reveal prior cases of primary, invasive, duodenal aspergillosis in patients with cirrhosis or diabetes.…”

Section: Case Reportmentioning

confidence: 80%